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Abstract 
Review on NR0B1, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: AHC, AHCH, AHX, DAX-1, 
DAX1, DSS, GTD, HHG, NROB1, SRXY2 
HGNC (Hugo): NR0B1 
Location: Xp21.2 
Note: Locus type: gene with protein product. 
DAX-1 is an unusual orphan nuclear receptor 
playing a pivotal role in the development and 
function of steroidogenic tissues, being responsible 
for the human disease adrenal hypoplasia congenita 
(AHC). Moreover, it controls embryonic stem (ES) 
cell differentiation and is implicated in the 
pathogenesis of several types of cancers. 
DNA/RNA 
Note 
A region of approximately 160 kb, whose 
duplication is responsible for male-to-female sex 
reversal, was identified on chromosome Xp21. The  
genetic disorder characterized by this duplication 
was indicated as Dosage-Sensitive Sex reversal 
(DSS) (Bardoni et al., 1994). This chromosomal 
region harbors the NR0B1 gene (Zanaria et al., 
1994). Mutations in NR0B1 cause adrenal 
hypoplasia congenita (AHC), a congenital disease 
of the adrenal cortex, which is associated to 
hypogonadotropic hypogonadism (HHG) at 
puberty. The gene was initially designated DAX-1, 
which stands for DSS, AHC locus on the X-
chromosome, gene 1 (Zanaria et al., 1994, 
Muscatelli et al., 1994). It encodes an orphan 
member of the nuclear receptor family and was 
later termed NR0B1 (nuclear receptor subfamily 0, 
group B, member 1) according to the standard 
nomenclature system for nuclear receptors. 
Description 
Size: 4.96 kb, 2 exons. mRNA: 1.9 kb.  
DAX-1 has two exons separated by an intronic 
region. Most of the coding sequence is found in 
exon one (McCabe et al., 2001; Burris et al., 1996), 
which encodes the N-terminal domain and part of 
the C-terminal domain of the protein, whereas exon 
two encodes the remaining part of the C-terminal 
domain. 
 
Figure 1. DAX-1 chromosomal localization. The DAX-1 gene maps on chromosome Xp21.3-p21.2 (adapted from GeneCards). 
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Figure 2. Schematic diagram of the DAX-1 protein. The DAX-1 protein (470 aa) harbors an N-terminal domain (blue box) and 
a C-terminal nuclear receptor ligand binding-like domain (pink box). The three repeats of about 70 aa in length and the fourth 
incomplete repeat in the N-terminal region are indicated by arrows. 
 
Protein 
Description 
The C-terminal portion of DAX-1 has homology to 
the ligand-binding domain (LBD) of nuclear 
receptors, although no ligands have been described 
to bind to the protein, thus explaining its 
classification as an orphan receptor. All features 
constituting the nuclear receptor LBD fold are 
present in DAX-1 C-terminal domain, as shown by 
homology models based on the crystal structure of 
apo-retinoic X receptor-α, holo-retinoic acid 
receptor-α and thyroid hormone receptor α (Lalli et 
al., 1997; Zhang et al., 1998). A conserved 
ΦΦXEΦΦ motif has been identified in the C-
terminal H12 helix, which in other nuclear 
receptors has been shown to be essential for ligand-
dependent transcriptional activation (AF-2, 
activation function 2). A potent transcriptional 
silencing domain is present in the DAX-1 C-
terminus (Lalli et al., 1997) and no ligands are 
known that can convert DAX-1 from a 
transcriptional repressor to an activator. Mutations 
causing AHC/hypogonadotropic hypogonadism 
(HHG) invariably disrupt the C-terminal domain of 
the protein, leading to the loss of the transcriptional 
repressor activity of the molecule (see Mutations 
below) (Zanaria et al., 1994; Muscatelli et al, 1994; 
Ito et al., 1997; Lalli et al., 1997). This is due to 
altered nuclear localization of DAX-1 AHC 
missense mutants induced by protein misfolding 
(see Mutations below) (Lehmann et al., 2002; 
Lehmann et al., 2003). 
DAX-1 structure is unusual when compared with 
other members of the nuclear receptor family, as it 
lacks the canonical DNA-binding domain (DBD), 
the AF-1 transcriptional activation domain and the 
hinge region.  
Instead, the N-terminus is constituted by three 
repeats of a unique cysteine-rich motif of about 70 
aminoacids (aa) in length.  
The number of repeats varies during evolution. 
Non-mammalian species display only one repeat 
(Smith et al., 2000; Western et al., 2000; Sugita et 
al., 2001, Wang et al., 2002). 
Protein translation: 
MAGENHQWQGSILYNMLMSAKQTRAAPEAP
ETRLVDQCWGCSCGDEPGVGREG 
LLGGRNVALLYRCCFCGKDHPRQGSILYSML
TSAKQTYAAPKAPEATLGPCWGCSC 
GSDPGVGRAGLPGGRPVALLYRCCFCGEDHP
RQGSILYSLLTSSKQTHVAPAAPEA 
RPGGAWWDRSYFAQRPGGKEALPGGRATAL
LYRCCFCGEDHPQQGSTLYCVPTS 
TNQAQAAPEERPRAPWWDTSSGALRPVALKS
PQVVCEAASAGLLKTLRFVKYLPC 
FQVLPLDQQLVLVRNCWASLLMLELAQDRL
QFETVEVSEPSMLQKILTTRRRETGG 
NEPLPVPTLQHHLAPPAEARKVPSASQVQAIK
CFLSKCWSLNISTKEYAYLKGTVLFN 
PDVPGLQCVKYIQGLQWGTQQILSEHTRMTH
QGPHDRFIELNSTLFLLRFINANVIAE 
LFFRPIIGTVSMDDMMLEMLCTKI 
Sequence length: 470 aa. Molecular weight: 51,718 
kDa. 
An alternatively spliced isoform of DAX-1 has 
been described in human tissues (Ho et al., 2004; 
Hossain et al., 2004). The protein DAX-1A or 
DAX-1α contains the first 389 aa of DAX-1 
followed by a novel 12-aa motif. It thus lacks the 
last 70 aa of the DAX1 C-terminal domain, which 
includes part of the transcriptional silencing domain 
and the AF-2 motif. However, the expression levels 
of this isoform are extremely low in steroidogenic 
tissues (Nakamura et al., 2009b). 
Expression 
DAX-1 is expressed in tissues involved in steroid 
hormone production and reproductive function, i.e. 
adrenal cortex, testicular Leydig and Sertoli cells, 
ovarian theca and granulosa cells, pituitary 
gonadotropes, ventromedial hypothalamic nucleus 
in the brain and some other brain areas (arcuate 
nuclei, amygdala, hippocampus, cerebral cortex) 
(Ikeda et al., 1996; Swain et al., 1996; Tamai et al., 
1996; Ikeda et al., 2001). This expression pattern is 
strikingly overlapping with that of another nuclear 
receptor, steroidogenic factor 1 (SF-1; NR5A1), a 
master regulator of adrenocortical gonadal and 
gonadotrope development and function (reviewed 
in Parker and Schimmer, 1997; Lalli et al., 2013). 
Localisation 
Studies on cultured cells and the developing mouse 
pituitary show that DAX-1 is present both in the 
nucleus and the cytoplasm (Lalli et al., 2000; 
Lehmann et al., 2002; Holter et al., 2002; Kawajiri 
et al., 2003; Clipsham et al., 2004). Moreover, 
DAX-1 is able to homodimerize in both these 
subcellular compartments (Iyer et al., 2006) and 
associates with polyribosomes via mRNA, 
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functioning as a shuttling RNA binding protein (see 
Role in transcriptional regulation below) (Lalli et 
al., 2000). 
Function 
Role in transcriptional regulation 
Starting from the studies which show that DAX-1 
expression pattern overlaps with that of SF-1 (see 
Expression above), it was demonstrated that DAX-
1 inhibits SF-1 - mediated transactivation and 
steroid hormone production (Ito et al., 1997; 
Zazopoulos et al., 1997). Indeed DAX-1 contains a 
powerful transcriptional repression domain in its C-
terminus (see Protein; Description above) 
overlapping with its nuclear receptor LBD domain 
(Ito et al., 1997; Lalli et al., 1997), through which it 
acts as a negative regulator of SF-1-induced 
transactivation. DAX-1 binds to gene promoters 
regulated by SF-1 (e.g. StAR and Dax-1 promoters, 
Zazopoulos et al., 1997) or it directly interacts with 
SF-1 (via one of the LXXLL motifs in the DAX-1 
N-terminus), thus repressing SF-1 transactivation 
(Suzuki et al., 2003). On the other hand, SF-1 
enhances Dax-1 expression through binding to its 
promoter (Kawabe et al., 1999), probably 
establishing a negative feedback loop to limit SF-1 
action in steroidogenic and reproductive tissues. 
DAX-1 inhibits the steroidogenic process at various 
levels. It acts both on the steroidogenic acute 
regulatory protein (StAR)-mediated rate-limiting 
step of cholesterol import into mitochondria, but 
also on the expression of CYP11A1 and 3-β-
hydroxysteroid dehydrogenase (HSD3B2) 
(Zazopoulos et al., 1997; Lalli et al., 1998). The 
presence of cells expressing DAX-1 but not SF-1 in 
different organs (Ikeda et al., 2001) suggests that 
DAX-1 function extends beyond the regulation of 
SF-1 - dependent genes. Indeed, DAX-1 inhibits the 
transcriptional activity of multiple transcription 
factors, like retinoic acid receptor α (RARα) and 
retinoid X receptor α (RXRα) (Zanaria et al., 1994), 
liver receptor homologue-1 (LRH1) (Suzuki et al., 
2003), estrogen receptors α and β (ERα and ERβ) 
(Zhang et al., 2000), glucocorticoid receptor (GR) 
(Zhou et al., 2008), androgen receptor (AR) (Holter 
et al., 2002; Agoulnik et al., 2003), progesterone 
receptor (PR) (Agoulnik et al., 2003), nerve growth 
factor-inducible gene B (NGFIB; also known as 
Nurr 77) (Song et al., 2004), estrogen-related 
receptor γ (ERRγ) (Park et al., 2005), peroxisome 
proliferator-activated receptor gamma (PPARγ) 
(Kim GS et al., 2008), hepatocyte nuclear factor 4 
(HNF-4) (Nedumaran et al., 2009). The 
mechanisms through which DAX-1 inhibits the 
transcriptional activity of those transcription factors 
involve both DNA binding and heterodimerization 
(Zanaria et al., 1994; Zazoupoulos et al., 1997; 
Zhang et al., 2000; Suzuki et al., 2003). It has been 
suggested that DAX-1 interacts with the coactivator 
groove of the nuclear receptors' LBD through its N-
terminal LXXLL motifs (Zhang et al., 2000), 
However, recently a structural study has shown that 
mouse Dax-1 interacts with LRH-1 as a homodimer 
via an unusual C-terminal repressor helix (Sablin et 
al., 2008). DAX-1 - mediated transcriptional 
repression involves interaction with corepressors. 
They can silence the activity of the basal 
transcriptional machinery and/or lead to chromatin 
modifications. For example, the N-CoR (Crawford 
et al., 1998) and Alien (Altincicek et al., 2000) 
corepressors have been reported to interact with 
DAX-1. However, when DAX-1 surface residues 
(which in other nuclear receptors are involved in 
direct interaction with corepressors) are mutated, 
DAX-1 transcriptional silencing properties are not 
perturbed (Lehmann et al., 2003). These data 
indicate that cofactors other than known nuclear 
receptor corepressors may mediate DAX-1 
transcriptional silencing activity. 
DAX-1 nucleo-cytoplasmic shuttling, RNA binding 
activity and association with actively translating 
polyribosomes as part of a messenger 
ribonucleoprotein complex in steroidogenic cells 
suggest that this factor has a role in post-
transcriptional regulations (Lalli et al., 2000). 
Overall, from the analysis of DAX-1 - regulated 
genes (reviewed in Lalli and Sassone-Corsi, 2003), 
it clearly emerges that DAX-1 acts as a global 
negative regulator of steroid hormone production 
by silencing the expression of multiple genes 
involved in steroidogenesis (Lalli et al., 1998). 
Role in sexual differentiation 
Based on DAX-1 gene localization inside the 
critical region in Xp21, whose duplication causes 
the DSS syndrome (see Implicated in section 
below) (Bardoni et al., 1994), a role for this factor 
in the sexual differentiation process has been 
hypothesized. 
In the mouse, the Dax-1 transcript is first detectable 
in the genital ridge at 11.5 days post coitum (dpc) 
and was shown to be downregulated in the male 
gonad but still expressed in the developing ovary at 
later times (Swain et al., 1996). Furthermore, 
gonadal female differentiation was induced by the 
overexpression of a genomic DNA fragment 
containing the Dax-1 gene in mouse strains 
harboring a "weak" Sry allele (M. domesticus 
poschiavinus, Sry transgenic XX animals) (Swain 
et al., 1998). On the basis of these findings in mice 
and the DSS phenotype in humans, an essential role 
as an "antitestis gene" was initially attributed to 
DAX-1 (Goodfellow and Camerino, 2001). In 
contrast with those results, the Dax-1 transcript was 
still detected at equivalent levels in mouse and rat 
testis and ovary at 12.5-15.5 dpc and was shown to 
be downregulated in the ovary at later stages (Ikeda 
et al., 1996; Nachtigal et al., 1998). The Dax-1 
protein is also expressed in both testis Sertoli and 
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Leydig cells and throughout the ovarian 
primordium at 12.5-14.5 dpc in the mouse (Ikeda et 
al., 2001). Moreover, DAX-1 transcripts were 
detected in human embryos both in the male and 
female gonadal ridges during the critical period of 
sex determination (Hanley et al., 2000). Finally, 
during embryogenesis the expression of DAX-1 
homologues both in the male and the female gonad 
has been reported in pig, chicken, alligator, frog and 
some fish species (reviewed in Lalli and Sassone-
Corsi, 2003). Collectively, these findings suggest 
that DAX-1 exerts a specific function in distinct 
cell populations both in the male and in the female 
gonads. While essential in males, multiple evidence 
indicates that DAX-1 activity is dispensable in 
female gonadal development. Indeed DAX-1 
regulates the development of peritubular myoid 
cells and the formation of testis cords, thus being 
crucial for testis differentiation (Meeks et al., 
2003a). Its absence has been linked to male-to-
female sex reversal in certain genetic backgrounds, 
associated with a failure in upregulation of Sox9 
expression in the developing male gonad (Meeks et 
al., 2003b; Bouma et al., 2005; Park et al., 2008). 
Moreover, spermatogenesis defects where identified 
in the testis of AHC/HHG patients, which display 
disorganization of seminiferous tubular structures 
and Leydig cell hyperplasia (Seminara et al., 1999, 
Mantovani et al., 2002). On the other hand, Dax-1 
null mice do not display ovarian defects or 
AHC/HHG, but instead develop a progressive 
degeneration of the testicular germinal epithelium 
(Yu et al., 1998). Furthermore, a female individual 
carrying a homozygous nonsense mutation in DAX-
1 and affected by isolated HHG exhibited normal 
ovaries (Merke et al., 1999). Collectively, these 
findings show that DAX-1 is important for male, 
but not female gonad development and function. 
To explain the female or ambiguous gonadal 
differentiation phenotype in XY individuals upon 
DAX-1 overexpression (due to duplication 
affecting Xp21) (Bardoni et al., 1994), two 
molecular mechanisms have been proposed (Lalli 
and Sassone-Corsi, 2003): 
1. Repression of MIS production by fetal Sertoli 
cells. This is due to DAX-1 inhibitory action during 
male sexual development on the synergistic 
interaction of SF-1 and Wilms tumor 1 (WT1), 
which activates the MIS gene promoter (Nachtigal 
et al., 1998). DAX-1 also inhibits the transcriptional 
cooperation between GATA4 and SF-1 (Tremblay 
and Viger, 2001), which acts to mediate the 
expression of MIS. DAX-1 overexpression would 
thus repress the expression of MIS during the stage 
crucial for sexual differentiation. 
2. Repression of testosterone production by fetal 
Leydig cells. Given DAX-1 negative role on 
steroidogenesis, its overexpression would inhibit 
testosterone biosynthesis in fetal Leydig cells and 
thus impair sexual secondary character 
masculinization. 
More recently, another mechanism for DAX-1 
overexpression in interfering with normal male sex 
determination has been proposed, that involves 
inappropriate repression of SF-1 activation of the 
testis SOX9 enhancer (Ludbrook et al., 2012). 
Role in adrenal development 
In the developing human adrenal cortex, a gradient 
of DAX-1 expression exists from the outer, 
definitive zone (form which the adult adrenal cortex 
will be formed) to the internal, fetal zone that 
produces high amount of steroids (Battista et al., 
2005). Adrenocorticotropic hormone (ACTH) 
stimulation leads to nuclear localization of DAX-1 
in fetal cells cultured on collagen, while angiotensin 
II promotes protein localization only in the 
cytoplasm in fetal cells cultured on either collagen 
or fibronectin (Battista et al., 2005). A model has 
been proposed whereby DAX-1 inhibits the 
expression of steroidogenic genes in definitive zone 
cells, whereas its cytoplasmic localization in fetal 
zone cells allows for production of high levels of 
steroids (Lalli and Sassone-Corsi, 2003). The loss 
of function of DAX-1 in AHC would stimulate 
enhanced differentiation in adrenal definitive zone 
cells through the abnormal early expression of 
genes involved in steroid hormone production and 
the depletion of progenitor cells, thus causing 
adrenal hypoplasia and insufficiency. The 
physiological regression of the fetal zone would 
then produce adrenal hypoplasia. 
During mouse adrenal development, Dax-1 
expression has been described in the adrenal 
primordium (AP) starting from E10.5, being readily 
detectable at E12.5. At this stage, the expression 
pattern of DAX-1 overlaps with that of SF-1, whose 
expression is driven by the fetal adrenal enhancer 
(FAdE) (Zubair et al., 2008). Later, DAX-1 is 
found in the outer part of the AP (from which the 
adult adrenal cortex will originate), whereas FAdE 
expression is restricted to the inner part of the 
adrenal cortex (identified as the X-zone 
postnatally). These data suggest that Dax-1 may 
suppress FAdE expression during the transition 
from the fetal to the adult adrenal differentiation 
program and suggests that a fine balance between 
SF-1 and DAX-1 is needed for normal 
adrenocortical development. This also helps to 
explain how loss of function of two transcription 
factors as SF-1 and DAX-1, one activator and one 
repressor of transcription, leads to the same adrenal 
hypoplasia phenotype. 
Role in embryonic stem cells 
In 2003 Dax-1 has been identified as one of the 
transcripts that are highly expressed in mouse ES 
cells (Mitsui et al., 2003). Later, it was reported that 
differentiation of mouse ES cells is induced by 
Dax-1 knockdown by RNA interference or gene 
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inactivation by homologous recombination (Niakan 
et al., 2006). More recently, it has been shown that 
Dax-1 is part of the core protein network which 
controls murine ES cells pluripotency and self-
renewal through the interaction with other key 
factors and binding to a common group of gene 
promoters (Loh et al., 2006; Wang et al., 2006; Kim 
J et al., 2008). The essential pluripotency factors 
STAT3, Oct3/4 and Nanog control Dax-1 
expression in mouse ES cells (Loh et al., 2006; 
Wang et al., 2006; Sun et al., 2008). Dax-1, in turn, 
binds to Oct3/4 to limit its transcriptional activity 
and thus avoid loss of ES cell pluripotency (Sun et 
al., 2009). It has been recently reported that β-
catenin - dependent transcription affects DAX-1 
expression in mouse ES cells and that Dax-1 
knockdown rapidly induces the upregulation of 
early differentiation markers belonging to the three 
embryonic germ layers. This in turn causes 
enhanced differentiation at the cellular level and 
defects in ES viability and proliferation (Khalfallah 
et al., 2009). Indeed, Dax-1 has been reported to be 
rapidly downregulated at the mRNA and protein 
level by different treatments promoting ES cell 
differentiation (Khalfallah et al., 2009). Dax-1 also 
exerts its transcriptional repression activity in 
murine ES cells as in steroidogenic cell types and 
both its N-terminal and C-terminal domains exhibit 
a promoter-specific transcriptional silencing action 
(Khalfallah et al., 2009). Altogether these findings 
indicate that Dax-1 is an essential element in the 
molecular circuit involved in the maintenance of ES 
cell pluripotency. Indeed previous studies proposed 
an "additive" model for gene regulation in murine 
ES cells whereby promoters bound by only a 
limited number of pluripotency factors (including 
Dax-1) tend to be inactive or repressed, whereas 
promoters bound by more than four factors are 
active in the pluripotent state and repressed upon 
differentiation (Kim J et al., 2008). Lalli and 
Alonso proposed that Dax-1 is not to be considered 
as an essential pluripotency factor in murine ES 
cells, but rather that it acts as a specialized 
pluripotency keeper that mediates repression of a 
subset of differentiation genes under the control of 
upstream pluripotency factors (Lalli and Alonso, 
2010). Remarkably, in human ES cells very low 
levels of DAX-1 are present and its expression is 
inconsistently modulated during their 
differentiation (Xie et al., 2009). This suggests that 
the pluripotency keeper role of DAX-1 in mouse ES 
cells is not conserved in human or that redundant 
pathways are activated. 
Homology 
Interspecies 
Ortholog to NR0B1, Pan troglodytes 
Ortholog to Nr0b1, Mus musculus 
Ortholog to Nr0b1, Rattus norvegicus 
Ortholog to nr0b1, Danio rerio 
Mutations 
Note 
Since the identification of DAX-1 mutations as the 
cause of AHC (Muscatelli et al., 1994; Zanaria et 
al., 1994), several DAX-1 mutations have been 
described in individuals or families with X-linked 
AHC (reviewed in Jadhav et al., 2011). They 
include deletions, alterations of splice sites, 
missense, nonsense and frameshift mutations 
(deletions, insertions, duplications and complex 
deletions/insertions). Missense mutations represent 
about one-quarter of DAX-1 mutations and are 
localized in nearly all cases in the C-terminal 
domain of the protein (Lin et al., 2006).  
The common feature of DAX-1 mutations causing 
AHC/HHG is that they affect the integrity of the 
protein C-terminal domain and impair 
transcriptional repression by DAX-1 (Muscatelli et 
al., 1994; Zanaria et al., 1994; Lalli et al., 1997; Ito 
et al., 1997; Crawford et al., 1998; Altincicek et al., 
2000; Tabarin et al., 2000; Achermann et al., 2001). 
From the analysis of several different DAX-1 
missense mutations found in AHC patients, it 
emerged that the impairment of transcriptional 
repression is dependent on an altered nuclear 
localization of the mutant proteins, which are not 
able to repress target gene expression, being 
retained in the cytoplasm (Lehmann et al., 2002; 
Lehmann et al., 2003). Remarkably, DAX-1 AHC 
mutant proteins localize in the cytoplasm, even if 
their nuclear localization signal (NLS), which 
resides in the N-terminal of the protein, is intact. A 
direct correlation between the cytoplasmic 
localization of DAX-1 AHC mutants and the 
reduction of their transcriptional silencing activity 
has been reported. Interestingly, the effect of AHC 
mutations was also observed when the protein C-
terminus was fused to a heterologous NLS-
containing DBD (Lehmann et al., 2002).  
It has been shown that DAX-1 AHC mutants are 
more affected by limited proteolysis than the wild-
type protein (Lehmann et al., 2003). As folded 
proteins have lower sensitivity to protease digestion 
than unfolded or misfolded polypeptides, these 
findings suggest that AHC mutations induce a 
misfolded state of the proteins, consistent with their 
localization at the level of certain residues that 
make critical contacts and stabilize the DAX-1 C-
terminal domain. The misfolding of DAX-1 AHC 
mutants may explain the reduced RNA-binding 
capacity, which depends both on the N- and C-
terminal domains of the protein (Lalli et al., 2000). 
Importantly, in addition to an impairment of 
transcriptional repression activity, DAX-1 AHC 
mutations may perturb protein nucleo-cytoplasmic 
shuttling and DAX-1 association to polyribosomes.  
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By structure-function analysis it has been 
demonstrated that the substitution of DAX-1 
residues affected by AHC mutations with residues 
of analogous chemical nature does not alter protein 
function and localization, whereas substitution of a 
hydrophobic residue with a charged one (e.g. 
V269R, W291R) or of a charged residue with one 
of opposite charge (e.g. K382E, R425E) has the 
same consequences as AHC mutations (Lehmann et 
al., 2003). Notably, the I439S DAX-1 mutation, 
found in a patient affected by late-onset adrenal 
insufficiency and incomplete HHG, only partially 
perturbs protein nuclear localization and causes 
incomplete loss of DAX-1 transcriptional 
repression activity (Lehmann et al., 2002).  
Finally, evidence indicates that also the DAX-1 
helix 12 contains critical determinants for nuclear 
localization and transcriptional repression, as 
shown by the two AHC mutations M462stop and 
L466R (Lehmann et al., 2002; Lehmann et al., 
2003).  
Only two missense mutations have been reported to 
occur in the DAX-1 N-terminal region, the C200W 
mutation, associated with late-onset AHC (Bernard 
et al., 2006) and the W105C mutation, associated 
with isolated mineralocorticoid deficiency (Verrijn 
Stuart et al., 2007). Interestingly, a mild form of 
AHC was diagnosed in a patient carrying the 
nonsense mutation Q37X, predicted to cause a 
severe truncation of the protein, because of the 
expression of a partially functional amino-truncated 
of DAX-1 generated from an alternate in-frame 
translation start site (Ozisik et al., 2003). 
Implicated in 
Ewing tumors 
Note 
The Ewing family of tumors represents the cancer 
type where DAX-1 role and mechanisms of action 
have been better established. These highly 
malignant bone and soft tissue tumors are typical of 
children, adolescents and young adults. They derive 
from specific balanced chromosomal translocations, 
which lead to the expression of chimeric proteins 
harboring the N-terminus of the EWS gene product 
and the C-terminus of FLI1, a member of the ETS 
family of transcription factors (Arvand and Denny, 
2001). While DAX-1 expression has been reported 
in Ewing tumors, it is not expressed in 
neuroblastoma and embryonal rhabdomyosarcoma, 
which are histologically similar small-round-cell 
tumors (Mendiola et al., 2006). The EWS/FLI1 
fusion protein activates DAX-1 expression through 
the binding to a highly polymorphic GGAA-rich 
region in its promoter (García-Aragoncillo et al., 
2008; Gangwal et al., 2008). Remarkably, a 
positive correlation exists between DAX-1 
expression levels in Ewing tumor cells and the 
number of GGAA repeats at the level of the DAX-1 
promoter (García-Aragoncillo et al., 2008). DAX-1 
is required for Ewing tumor cell growth (García-
Aragoncillo et al., 2008; Kinsey et al., 2006). In 
fact, its knockdown in Ewing cells caused 
accumulation in the G1 phase of the cell cycle, 
inhibition of cell proliferation in vitro and 
impairment of xenotransplanted cell growth in 
mice. Interestingly, despite the continued 
expression of the EWS/FLI-1 oncoprotein, the 
effect of DAX-1 knockdown on the proliferation of 
Ewing cells was still observed. This suggests that 
DAX-1 is a main mediator of EWS/FLI1-induced 
cell proliferation. In fact, from gene expression 
profiling it emerged that about 10% of the genes 
controlled by EWS/FLI1 in Ewing tumor cells are 
targets of DAX-1. Most of these genes participate 
in cell cycle control, particularly in the G1/S 
transition, like CDK2, SKP2, MCM10 and CDC6 
(García-Aragoncillo et al., 2008). Collectively these 
data provide evidence for a key role played by 
DAX-1 in the acquisition of a transformed 
phenotype by Ewing tumor cells and indicate that 
DAX-1 can represent a molecular target for the 
treatment of this type of cancer. 
Adrenocortical tumors 
Note 
In adrenocortical adenomas DAX-1 expression 
levels inversely correlate with hormone production 
(with aldosterone-producing adenomas exhibiting 
the lowest DAX-1 levels) (Reincke et al., 1998). In 
contrast, DAX-1 expression in adrenocortical 
carcinoma is extremely variable (Reincke et al., 
1998). Low DAX-1 expression was confirmed in 
aldosterone-producing adenomas by another study 
(Lefrançois-Martinez et al., 2004) and was also 
present in cortisol-producing adenomas (Shibata et 
al., 2001). High DAX-1 levels were instead found 
in two cases of the rare deoxycorticosterone-
producing adenomas, which cause a syndrome of 
mineralcorticoid excess (Shibata et al., 2001). 
Collectively these studies show the existence of an 
inverse correlation between the levels of DAX-1 
expression and steroid hormone production in 
adrenocortical cancers. They also suggest that 
DAX-1 may affect the pattern of steroid hormones 
secreted by the tumor. Moreover, considering that 
DAX-1 acts as a repressor of SF-1 transcriptional 
activity (see Role in transcriptional regulation), its 
expression may represent an important mechanism 
to limit SF-1 pro-proliferative effect in 
adrenocortical cancer cells. Indeed, it has been 
demonstrated that SF-1 controls human 
adrenocortical cancer cell proliferation and tumor 
formation in mice in a dosage-dependent manner 
(Doghman et al., 2007; Doghman and Lalli, 2009). 
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Ovarian cancer 
Note 
A positive correlation between DAX-1 
immunoreactivity and clinical stage, tumor grade, 
residual size of the tumor after neoadjuvant 
treatment and tumour Ki-67 labelling index has 
been reported for ovarian carcinoma (Abd-Elaziz et 
al., 2003). The same group showed a significant 
inverse correlation between DAX-1 
immunoreactivity and patient survival. 
Breast cancer 
Note 
DAX-1 immunoreactivity positively correlates with 
AR levels and nodal status in human breast cancer 
(Conde et al., 2004). 
Endometrial cancer 
Note 
An inverse correlation was reported in endometrial 
carcinoma between DAX-1 immunoreactivity and 
histological grade, while a positive correlation with 
ERα and ERβ was shown (Saito et al., 2005). 
Prostate cancer 
Note 
A negative correlation between DAX-1 
immunoreactivity and Gleason score (a system used 
to assess the grade of malignancy) has been 
reported for prostate cancer (Nakamura et al., 
2009a).  
The commercial antibody used in most of the above 
studies does not specifically recognize DAX-1 in 
immunohistochemistry and Western blotting 
(Helguero et al., 2006; Lalli, 2013). This may create 
problems in the interpretation of data concerning 
DAX-1 expression in cell lines and tissues. 
Lung cancer 
Note 
Microarray analysis showed that DAX-1 expression 
is high in lung cancer stem cells identified among 
A549 cells by Hoechst 33342 staining (side 
population: SP) (Seo et al., 2007). Interestingly, 
only SP cells were tumorigenic after injection in 
immunodeficient mice (Hadnagy et al., 2006). This 
suggests that DAX-1 may participate in the 
maintenance of cancer stem cells in some type of 
cancers, as shown for mouse ES cells (see Role in 
embryonic stem cells above). Moreover, it has been 
recently reported that DAX-1 silencing does not 
affect A549 cells proliferation, whereas it increases 
their sensitivity to topotecan (topoisomerase I 
inhibitor) and decreases the ability of cells to 
invade through Matrigel, colony formation in vitro 
and xenograft growth in mice (Oda et al., 2009). A 
positive correlation also exists between DAX-1 
levels and nodal stage and tumor recurrence in lung 
adenocarcinoma. Promoter demethylation might be 
the cause of the high DAX-1 expression in a subset 
of lung adenocarcinoma samples. Indeed, it has 
been shown that low DAX-1 expression levels 
correlate with patient longer and disease-free 
survival (Oda et al., 2009). These results are 
promising for future studies on the role of DAX-1 
in lung adenocarcinoma and potential related 
therapeutic strategies. 
X-linked adrenal hypoplasia 
congenita (AHC) and 
hypogonadotropic hypogonadism 
(HHG) 
Note 
X-linked AHC is a disorder of adrenal gland 
development first described by Sikl in 1948, which 
occurs in fewer than 1:12,500 live births (Sikl et al., 
1948; McCabe, 2001). It is characterized by a small 
and hypofunctional adrenal gland and absence of 
the adrenal cortex permanent zone, with residual 
cytomegalic cells (Uttley, 1968; Mamelle et al., 
1975; McCabe, 2001). Adrenal insufficiency 
usually appears early in infancy; biochemical 
findings include low serum levels of 
glucocorticoids, mineralcorticoids and androgens 
and a failure to respond to ACTH stimulation 
(McCabe, 2001). AHC patients are generally 
treated with glucocorticoids and mineralcorticoids. 
Indeed, the disorder is lethal if untreated. This is 
due to dehydration and electrolyte imbalance as a 
consequence of mineralcorticoid deficit and to 
reduced resistance to stress. The X-linked 
syndrome constantly associates with HHG, which is 
diagnosed in patients affected by AHC who survive 
beyond pubertal age thanks to an appropriate 
hormonal replacement therapy. HHG is caused by 
combined hypothalamic failure in gonadotropin-
releasing hormone (GnRH) release and pituitary 
defect in the production of gonadotropin (Habiby et 
al., 1996). The onset of gonadotropin production is 
selectively impaired in patients affected by AHC-
associated HHG during puberty, while no 
perturbations of the physiological postnatal 
transient activation of the hypothalamic-pituitary-
gonadal axis are registered (Takahashi et al., 1997; 
Kaiserman et al., 1998).  
Phenotypic evaluation of patients with contiguous 
gene syndromes involving AHC along with various 
combinations of glycerol kinase deficiency, 
Duchenne muscular dystrophy, ornithine 
transcarbamoyltransferase deficiency and mental 
retardation allowed to narrow the locus to Xp21.3-
p21.2 (Hammond et al., 1985, Bartley et al., 1986, 
Francke et al., 1987; Goonewardena et al., 1989). 
The analysis of genes present in this region of the X 
chromosome led to the cloning of the DAX-1 gene, 
whose mutations (see Mutations above) are 
responsible for X-linked AHC/HHG (Zanaria et al., 
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1994; Muscatelli et al., 1994). The identification of 
DAX-1 as the gene responsible for X-linked AHC 
(Zanaria et al., 1994) had important implications for 
the diagnosis of individuals and families affected 
by this condition.  
From a study published in 2006 and aimed at 
investigating the prevalence of DAX-1 and SF-1 
mutations in children and adults affected by 
primary adrenal failure of unknown aetiology, it 
was estimated that DAX-1 mutations were present 
in 58% (37 of 64) of 46, XY phenotypic boys 
exhibiting adrenal hypoplasia and in all boys (8 of 
8) affected by HHG and with a family history 
reminiscent of adrenal failure in males (Lin et al., 
2006).  
DAX-1 deletions including both microdeletions 
within the coding sequence or promoter and very 
large deletions also involving adjacent genes were 
found in about one-third of AHC patients (Lin et 
al., 2006). 
Dosage sensitive sex reversal (DSS) 
Note 
DSS is a genetic defect, whose severity is variable 
with a list of signs and symptoms ranging from 
female external genitalia, ambiguous external 
genitalia and failed testicular development to streak 
gonads, primary amenorrhea and immature uterus. 
Male-to-female sex reversal was observed in 
patients with duplications of the X chromosome 
short arm (Bardoni et al., 1994). Bardoni and 
colleagues demonstrated that it originated from the 
presence of two active copies of an Xp locus. 
Alterations at this locus represented one of the 
causes of sex reversal in patients with a normal 
46,XY karyotype (Bardoni et al., 1994). The locus 
was termed DSS (Dosage Sensitive Sex reversal) 
and was localized to an Xp21 region of 60 kb 
adjacent to the AHC locus (Bardoni et al., 1994). 
The identification of males lacking the DSS locus 
indicated that it was not essential for testis 
differentiation, whereas it was proposed to 
participate in ovarian development and/or function 
as a link between the formation of ovary and testis 
(Bardoni et al., 1994). 
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